Y 931

Drug Profile

Y 931

Latest Information Update: 05 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation; Nonindustrial source
  • Class Antipsychotics
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 31 Mar 2004 Preclinical trials in Schizophrenia in Japan (unspecified route)
  • 31 Mar 2004 Preclinical trials in Schizophrenia in USA (unspecified route)
  • 31 Mar 2004 A preclinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top